PHIBRO ANIMAL HEALTH CORPORATION

Phibro Animal Health Corporation is a publicly traded company whose Class A common stock is listed on the Nasdaq Stock Market under the ticker PAHC. As a listed issuer, its shareholder disclosure is limited to holders that meet SEC reporting thresholds rather than a complete shareholder register.

The registry snapshot dated 4 September 2026 records two disclosed institutional holders: iShares Trust – iShares Core S&P Small-Cap ETF, holding approximately 9.05% of shares (1,221,411 shares), and Fidelity Salem Street Trust – Fidelity Small Cap Index Fund, holding approximately 1.52% of shares (205,555 shares). Both are index funds holding direct positions rather than controlling stakes.

The company’s controlling shareholder is BFI Co., LLC, described in Phibro Animal Health Corporation’s SEC filings as an investment vehicle of the Bendheim family. According to a Schedule 13D/A filed with the SEC, BFI Co., LLC beneficially owned 56,152 shares of Class A common stock and 19,496,034 shares of Class B common stock as of 22 May 2026, together representing about 48.2% of total shares outstanding. Because each share of Class B common stock carries ten votes compared with one vote per share of Class A common stock, the company’s proxy statement states that BFI Co., LLC controls a majority of the combined voting power of both classes, making Phibro Animal Health Corporation a controlled company under Nasdaq listing standards.

Ultimate beneficial ownership: Jack C. Bendheim, the company’s Chairman, President and Chief Executive Officer, is named in the same Schedule 13D/A as holding sole authority to vote all shares of common stock owned by BFI Co., LLC, and, together with certain other family members, acts as manager of BFI Co., LLC with respect to the economic rights attached to those shares. On this basis Mr. Bendheim may be deemed to beneficially own the shares held by BFI Co., LLC. No further natural-person owner above this level is disclosed in the sources reviewed.

Data availability: shareholder disclosure for Phibro Animal Health Corporation is best described as major shareholders only. SEC rules require disclosure of beneficial owners of 5% or more of a class of stock, together with directors’ and officers’ holdings, but do not require publication of a full shareholder register; smaller institutional and retail holdings are not individually disclosed.

Phibro Animal Health Corporation’s registry record lists 14 active officer entries, all recorded with the generic role of Governingperson under its Washington State filing and no appointment or resignation dates. The company’s SEC proxy statement, prepared for the 4 November 2025 annual meeting, provides more detailed and dated information on the current board of directors and named executive officers.

The board of directors comprises nine members: Jack C. Bendheim (Chairman, President and Chief Executive Officer, a director since 1984), Daniel M. Bendheim (director since November 2013 and Executive Vice President, Corporate Strategy), Jonathan Bendheim (Senior Vice President, Global Technology and Talent), Alejandro Bernal (director since February 2023), E. Thomas Corcoran (director since May 2008), Sam Gejdenson (director since January 2004), Joyce J. Lee (director since January 2025), Mary Lou Malanoski (director since May 2004), and Carol A. Wrenn (director since July 2010). Several of these names, including Carol A. Wrenn and Daniel Bendheim, correspond to entries also recorded as governing persons in the company’s Washington State filing.

Other named executive officers disclosed in the same proxy statement include Glenn David (Chief Financial Officer), Larry L. Miller (Chief Operating Officer), Judith A. Weinstein (Senior Vice President, General Counsel and Corporate Secretary), Anthony Andolino (Vice President, Finance and Treasurer), and Lisa A. Escudera (Senior Vice President, Human Resources); Weinstein, Andolino and Escudera also appear among the Washington State governing-person entries.

Nationality is not disclosed for any officer or director in either the registry record or the company’s SEC filings. The Washington State filing records a correspondence country of the United States for each officer, but this is a filing address rather than evidence of residence or nationality, and no separate country-of-residence information is disclosed.

Recent officer changes: Joyce J. Lee joined the board of directors in January 2025, according to the company’s proxy statement. No board or executive-management resignations or removals were identified in the sources reviewed.

Data availability: officer and director information for Phibro Animal Health Corporation is best described as full for current board members and named executive officers, since the company is subject to SEC proxy-disclosure rules, but historical appointment and resignation dates for the complete set of governing persons recorded in the underlying state filing are not published.

Phibro Animal Health Corporation is not an independent company; it is controlled by BFI Co., LLC, an investment vehicle of the Bendheim family. BFI Co., LLC is recorded in Phibro Animal Health Corporation’s own corporate-linkage data at the same Teaneck, New Jersey address as Phibro Animal Health Corporation’s headquarters, and SEC filings confirm that BFI Co., LLC holds a majority of the company’s combined voting power (see the shareholders section of this profile for the reported holdings and dates).

Phibro Animal Health Corporation itself has an extensive network of subsidiaries. Its Exhibit 21.1 subsidiary listing, filed with its Form 10-K for the fiscal year ended 30 June 2026, names more than 50 subsidiaries operating across more than 30 countries, including the United States, Canada, the United Kingdom, Ireland, Belgium, Italy, Poland, Turkey, Israel, South Africa, Argentina, Brazil, Chile, Colombia, the Dominican Republic, Mexico, Peru, Uruguay, Venezuela, China, Hong Kong, Indonesia, Malaysia, the Philippines, Thailand, Australia and Egypt. This exhibit does not disclose ownership percentages or intermediate ownership chains for these entities.

Verified corporate relationships (selected; not an exhaustive list):

Data availability: the group structure disclosed for Phibro Animal Health Corporation is best described as partial. The controlling-shareholder relationship is well documented through SEC beneficial-ownership filings, and a comprehensive subsidiary name list is available through SEC Exhibit 21.1, but that exhibit does not report intermediate ownership chains, ownership percentages, or subsidiary-level registration numbers, so the precise ownership path to each individual subsidiary cannot be independently verified from the sources reviewed.